Halt of Polyphor trial shrinks company valuation
Roche had a nose for success when the pharma giant ended the CHF500m deal with Polyphor in November 2015. Now, the antibiotics maker stopped a Phase III trial of its lead murepavadin (Pol7080).
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2080 entries already.
Entries by Thomas Gabrielczyk
Ethics Council calls for moratorium of clinical germline manipulation
Following the birth of genome-edited twins in China, the German Ethics Council has provided a complete ethical review about human germline intervention.
BioNtech aquires antibody assets from MabVax Therapeutics
MS linked to epigenetic changes in immune cells
Epigenetic changes in immune cells may provide the trigger of multiple sclerosis. Researchers have now identified MS-specific epigenetic biomarkers that change upon drug treatment.
Whitepaper Spotlight: Proactive Biomarker Planning to Optimize Clinical Trials
Oncology drugs developed through a biomarker-guided precision medicine design are 38% more likely to be commercialized. But success relies on following a plan from the start — learn how in this free whitepaper
Confo Therapeutics raise €30m in Series A financing
The round was led by BioGeneration Ventures and Wellington Partners, with Fund+, Perceptive Advisors and existing investors Capricorn Venture Partners, MINTS, PMV, QBIC and V-Bio Ventures contributing.
LEA Jury announces the Winners of LEA 2019
LEA, the Lipidomics Excellence Award, was founded to strengthen life sciences through lipidomics. Over the course of April, the LEA jury deliberated on the submitted projects to announce the three LEA awardees.
Researchers report how body fat affects imune cells
US scientists have found that the complex interactions between fat tissue and the immune system are mediated by interleukin 33 (IL-33).
European Lead Factory gets €36.5m support from IMI
The European Lead Factory (ELF) – a drug discovery hub for validation new targets from academia and biotech SMEs – has again received project funding from the Innovative Medicine’s Initiative.
AstraZeneca set to licence 5 programmes from Transgène SA
Transgène SA and AstraZeneca plc have entered into a collaboration and exclusive license option agreement on Transgène’s armed oncolytic immunotherapies.